Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1345 RSV vaccine in adults ≥50 years
NCT05330975Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Apr 2022
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RNA-100-AR02 in respiratory syncytial virus infection (RSV), sponsored by Moderna Inc. Started Apr 2022; status: completed.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05330975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330975.